Total joint replacement (TJR) is a common and effective surgical procedure for hip or knee joint reconstruction. However, the production of wear particles is inevitable for all TJRs, which activates macrophages and initiates an inflammatory cascade often resulting in bone loss, prosthetic loosening and eventual TJR failure. Macrophage Chemoattractant Protein-1 (MCP-1) is one of the most potent cytokines responsible for macrophage cell recruitment, and previous studies suggest that mutant MCP-1 proteins such as 7ND may be used as a decoy drug to block the receptor and reduce inflammatory cell recruitment. Here we report the development of a biodegradable, layer-by-layer (LBL) coating platform that allows efficient loading and controlled release of 7ND proteins from the surface of orthopedic implants using as few as 14 layers. Scanning electron microscopy and fluorescence imaging confirmed effective coating using the LBL procedure on titanium rods. 7ND protein loading concentration and release kinetics can be modulated by varying the polyelectrolytes of choice, the polymer chemistry, the pH of the polyelectrolyte solution, and the degradation rate of the LBL assembly. The released 7ND from LBL coating retained its bioactivity and effectively reduced macrophage migration towards MCP-1. Finally, the LBL coating remained intact following a femoral rod implantation procedure as determined by immunostaining of the 7ND coating. The LBL platform reported herein may be applied for in situ controlled release of 7ND protein from orthopedic implants, to reduce wear particle-induced inflammatory responses in an effort to prolong the lifetime of implants.
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Introduction
Total joint replacement (TJR) is a very common and successful procedure performed over 1 million times annually in the US on hips and knees alone. Despite the success of current TJR procedures, 38,000 revision total hip replacements (THRs) and 39,000 revision total knee replacements (TKRs) were performed in 2006, leading to costs in excess of 1 billion dollars for the procedures alone [1, 2] . Revision procedures are more costly and have a less predictable outcome. The revision procedure often results in increased bone loss, the requirement for bone grafts and more expensive implants. By the year 2030, the percentage of Americans over 65 years is expected to increase to 37%, from 19% in 1985, and result in further increasing needs for THRs and TKRs [3, 4] . Furthermore, TJRs are now been performed in younger patients with more active lifestyles, which places increased demands on their TJR. As a result, the major long-term problem associated with TJRs is in the generation of wear particle debris.
One major factor that contributes to the failure of TJR is the production of wear particles, which is inevitable for all TJRs. Wear begins during the initial "bedding in" phase of newly implanted TJRs and continues with use. The majority of TJRs incorporate a polyethylene bearing surface, and polyethylene wear particles are phagocytized by macrophages, which initiates activation of the inflammatory cascade. Pro-inflammatory cytokines, chemokines, prostanoids, reactive oxygen intermediates (ROIs) and other factors are released locally into the synovial fluid and interfacial tissues [5, 6] . These inflammatory mediators activate local osteoclasts and interfere with mesenchymal cell proliferation, differentiation and function, which delays initial implant osseointegration leading to peri-prosthetic bone resorption. Cells of the monocyte/macrophage lineage (macrophages, foreign body giant cells and osteoclasts) are among the key cells that perpetuate the inflammatory reaction to wear particles of orthopedic implants. The process begins when monocytes/macrophages are recruited to the site of wear particle production. Once monocytes/macrophages are recruited to the joint space, the presence of wear particles stimulates overexpression of inflammatory cytokines. Such inflammation in the joint space would also delay bone implant integration, and can result in implant failure. Therefore, there is a strong need to develop methods to modulate the inflammatory responses at the implantation site of orthopedic implants to inhibit undesirable macrophage trafficking.
Macrophage chemoattractant protein-1 (MCP-1) is one of the major cytokines responsible for monocyte/macrophage cell recruitment. The wild type MCP-1 protein is 76 amino acids long and signals through the CeC chemokine receptor type 2 (CCR2) and CCR4 receptors on the surface of monocytes. The N-terminal residues of MCP-1 are crucial in activating the MCP-1 signaling pathway. Previous studies have created mutant MCP-1 by removing the first 8 residues (QPDAINAP), and the resulting protein MCP-1 (9-76) can bind to CCR2 and CCR4 without activating the pathway [7, 8] . It has also been shown that removal of residues 2e8 (MCP-1 (1 þ 9-76)), also known as 7ND, produced a similarly inhibitory effect on monocyte recruitment [9e11]. In vivo release of 7ND from gene eluting stents was shown to attenuate stenosis in rabbits and monkeys by effectively reducing inflammatory cell recruitment [12] . These results suggest that mutant MCP-1 proteins such as 7ND may be used as a promising decoy drug to block the receptor, thereby inhibiting the undesirable monocyte/macrophage recruitment.
To modulate inflammatory responses at the implant site and minimize peri-prosthetic bone loss, it would be highly desirable to deliver 7ND locally to the peri-prosthetic space. A bolus delivery of 7ND at the time of implantation may inhibit the early stage recruitment of monocytes/macrophages, however, controlled release of 7ND would be preferred to achieve a prolonged antiinflammatory response. To achieve local delivery of 7ND, one promising strategy is to coat the protein onto the surface of the implant. Layer-by-layer (LBL) deposition provides an effective and facile method for loading biological molecules onto irregularly shaped material surfaces, and allows higher amounts of drug loading and more controlled release than surface adsorption. The LBL process involves sequential deposition of positively and negatively charged polyelectrolytes on the implant surface. Charged biomolecules can be substituted in place of a polyelectrolyte layer at any time throughout the layering process. The process can be repeated multiple times until the desired amounts of biomolecules have been loaded. However, most previously reported LBL platforms require lengthy coating process and the use of a large number layers to avoid burst release. For example, a 48-hr LBL coating process was required to achieve sufficient BMP-2 loading on the surface of PCL scaffolds for prolonged release and enhanced bone formation in vivo [13] . To decrease the initial burst release from a titanium surface, methods have been developed to add a large number of layers followed by chemical crosslinking of free amines within the LBL assembly [14] . However, this multi-step process is lengthy and requires incubation at low pH (pH 5.5) for up to 12 h, which may result in the loss of biological activity of the drugs.
To overcome the above limitations, we have recently reported an LBL platform that allows controlled protein release from polymeric scaffolds over a few weeks using a small number of layers that is an order of magnitude less than conventional methods [15] .
We also found that protein loading and release kinetics can be optimized by varying chemical structure of the positively charged polyelectrolytes [15] . Based on these observations, we hypothesize that our recently reported LBL platform may be applied to achieve multilayered coating on orthopedic implants, for local delivery of 7ND proteins to decrease monocyte migration towards MCP-1, thereby decreasing wear-particle initiated inflammatory responses (Fig. 1) . We further hypothesize that the release kinetics of 7ND can be modulated by varying the structures of polyelectrolytes used in LBL assembly. To test our hypotheses, we synthesized a small library of cationic polyelectrolytes with diverse chemical structures for constructing LBL assemblies. We then examined the effects of varying polymer structure and order of deposition on protein loading and release. Scanning electron microscopy was used to visualize LBL coating on the surface of titanium rods over time. Using an optimized layering strategy, we then coated 7ND onto the surface of titanium rods and evaluated the effects of cationic polyelectrolyte structure on 7ND release kinetics. The bioactivity of released 7ND from LBL coating was examined by quantifying the migration of THP1, a human monocytic cell line, using a transwell assay. Finally, we evaluated the LBL stability during a femoral implantation procedure by press fitting the coated titanium rods into the distal femur, and compared the surface structures pre-and post-implantation using SEM and fluorescence microscopy.
Materials and methods

Poly(b-amino)ester synthesis
End-modified poly(b-amino ester)s (PBAEs) were synthesized as previously described [16] . Briefly, a diacrylate monomer (C or D) (Sigma Aldrich, St. Louis, MO) was reacted with 5-amino-pentanol (32) (Sigma Aldrich) through a Michael addition reaction at 90 C ( Fig. 2A) . Both acrylate-terminated PBAEs were subsequently modified with four different amine end groups (Fig. 2B ) using molecules as shown in Fig. 2C . Following an overnight reaction at room temperature, amine-terminated PBAEs were extracted in anhydrous diethyl ether (Fisher Scientific, San Jose, CA), dissolved in anhydrous DMSO (Fisher Scientific) and stored at À20 C until use.
Preparation of polyelectrolyte solutions
The positively charged polyelectrolyte, PBAE, was dissolved in phosphate buffered saline (PBS) (Life Technologies, Grand Island, NY) or sodium acetate (25 mM) (Fisher Scientific) to reach a concentration of 10 mg/ml. Polystyrene sulfonate (PSS) (Sigma Aldrich) or chondroitin sulfate (CS) (Sigma Aldrich) was selected as the negatively charged polyelectrolytes and dissolved in H 2 O or sodium acetate (25 mM) to reach 3 mg/ml 7ND protein was dissolved in H 2 O containing bovine serum albumin (1 mg/ml) (Fisher Scientific) or sodium acetate (25 mM) to a final concentration of 30 mg/ml. BSA acts as a carrier protein for 7ND during the deposition process.
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Block Macrophage Migration Fig. 1 . Schematic demonstrating the design concept of the study, with controlled release of 7ND protein from layer-by-layer (LBL) coating on orthopedic implants to modulate inflammation. The released 7ND is designed to bind the MCP-1 receptor located on macrophages without activating the pathway, hence 7ND acts as an antagonist for MCP-1 to inhibit inflammation.
Combinatorial screening for the choice of polyelectrolytes on minimizing burst release from LBL coating
To examine the effects of varying negatively charged polyelectrolytes, both chondroitin sulfate (CS) (Groups 1e4) and polystyrene sulfonate (PSS) (Groups 5e8) were used as the negatively charged polyelectrolytes throughout the layering process for binding 7ND. Within each subset of groups, 4 PBAEs with different functional end-group chemistry were used as the positively charged polyelectrolytes including C32-130, C32-135, C32-140, C32-117. Alternatively, 7ND was bound directly to the positively charged PBAEs with various end-group chemistry (Groups 9e12 and 13e16), and PSS was used as the negatively charged layer for constructing the LBL assembly. Previous studies have demonstrated efficient deposition and controlled release using low pH due to an increase in polyelectrolyte charge density. To further examine the effects of varying pH, LBL coating was performed at pH5 (Groups 9e12) by dissolving polyelectrolytes and 7ND in 25 mM sodium acetate or neutral pH solution (Groups 13e16). For groups 13e16, 7ND was dissolved in BSA solution of 0.1% (w/v) (Groups 9e16). Detailed procedure for LBL assembly is described below.
Layer-by-layer coating of 7ND on titanium rods
Hollow A-40 titanium rods (6 mm, 21 G) were purchased from New England Small Tube, Litchfield, NH. 7ND recombinant protein is a mutant MCP-1 protein which lacks the N-terminal amino acids 2 through 8, and has been shown to function as a dominant negative inhibitor of MCP-1 [9, 17] . The 7ND in the current study was kindly provided by Dr. Egashira at Kyushu University, Japan. Titanium rods were surface etched first in acid solution to aid layer-by-layer (LBL) attachment. Specifically, titanium rods were placed in concentrated hydrochloric acid solution (37.3% w/v, Fisher Scientific) for 2 h. The rods were then washed extensively with H 2 O and rinsed 3 times in 70% ethanol (Fisher Scientific) for a total of 15 min. The rods were air dried before LBL deposition as illustrated in Fig. 3A , with precursor layers on the bottom and biological layers containing 7ND on the top. Each layer was deposited for 5 min, with the exception of 7ND layers, which were deposited for 10 min. The rods were washed twice in H 2 O between every layer with 30 s per wash. To measure the protein release from the LBL coating, coated rods were immediately placed in 150 ml of PBS containing 0.005% (w/v) BSA and supernatant was collected periodically, and replaced with fresh PBS/BSA. BSA was included in the collection solution to prevent 7ND adhesion to the tissue culture plastic. Collected supernatant from various time points was stored at À80 C until time of analysis. Given the similarities in structure between 7ND and MCP-1, released 7ND was quantified using Enzyme Linked Immunosorbent Assay (ELISA) for MCP-1 (Peprotech, Rocky Hill, New Jersey). The accumulative release of 7ND was monitored up to 1 week.
Characterizing the effects of LBL coating on implant surface morphology
To examine the morphology changes on implant surface during the coating process, titanium rods were characterized before and after the LBL coating using scanning electron microscopy (SEM) and fluorescence microscopy. Rods were surface coated with 50 Å of palladium before imaging. Micrographs were obtained using a SEM (Sigma, Zeiss, Oberkochen, Germany). Immunofluorescent imaging was also performed to allow direct visualization of 7ND deposition on the titanium rod. 
Chemotaxis assay
To determine if released supernatant remained bioactive, a cell chemotaxis assay was performed. Released supernatant from each rod at day 1 (55 ml/rod) was lyophilized overnight, and then resuspended in 55 ml of fully supplemented THP-1 cell culture medium containing 6.0 Â 10 4 cells and incubated for 1 h. Chemotaxis assays were performed using a ChemoTx Ò Disposable Chemotaxis System (NeuroProbe, Gaithersburg, MD) containing 8 mm pores. The inflammatory cytokine (10 ng/ml MCP-1) was placed in the bottom chamber while 55 ml of cells/supernatant were placed in the upper chamber. A linear dilution of THP-1 cells was also placed in the bottom chamber which served as a means to quantify the number of migrated cells. Following a 90-min incubation period, cells in the upper chamber were removed by aspiration and the porous membrane was removed. Cells in the bottom chamber were transferred to a 96 well plate. Each well of the bottom chamber was washed with 30 ml H 2 O which was transferred to the respective wells in the 96-well plate. The plate was transferred to a À80 C freezer for 2 h and returned to room temperature until fully thawed. The freezeethaw cycle was repeated 2 more times. To quantify the number of migrated cells, 100 ml of PicoGreen (Invitrogen) dye was added to each well and fluorescence was read at 480/520 nm using a plate reader (Spectramax M2e, Molecular Devices, Sunnyvale, CA). DNA content was converted to cell number using the linear dilution of THP-1 cells.
Evaluating the stability of LBL coating during a femoral implantation procedure
Fresh cadavers of six 7e8 weeks old C57Bl/6 male/female mice used for colony maintenance were obtained from Stanford animal facility with institutions approval. The patellar tendon was exposed through a 5 mm skin incision and the intercondylar notch of the distal femur was accessed through a medial parapatellar arthrotomy. A series of needles (25e21 gage) was then used to manually drill through the intercondylar notch to gain access to the medullary cavity. LBL coated titanium rods were fluorescently labeled as described above prior to implantation. A coated and fluorescence labeled titanium rod connected from one end to vinyl tubing, was then press fit into the medullary canal of the distal femur through the drill hole. To minimize the artificial damage to the coating, the femur with the rod still in place was dissected free of any soft tissues, detached from the hip and knee joints and split open by superficial, longitudinal incision. The rod was then lifted off from the remaining bone bed by holding it by the vinyl tubing. Titanium rods were imaged pre-and post-implantation via SEM and fluorescent microscopy as described above. Analysis of fluorescence was accomplished using NIH ImageJ software by quantifying density of brightness for each rod. The background brightness density was subtracted from the rod brightness density to determine the corrected total fluorescence (CTF).
Statistical analysis
MinitabÔ (Minitab Inc., USA) software was used for statistical analysis. One-way analysis of variance (ANOVA) with a Tukey's post-hoc analysis was used to determine statistical significance between groups while a paired T-test was used to directly compare two groups. A value of p < 0.05 was considered statistically significant.
Results and discussion
Constructing 7ND-containing LBL assembly using PBAE
PBAEs were synthesized by a 2-step Michael addition reaction, in which various amine end capping groups were conjugated to hydrolytically degradable backbone polymers (Fig. 2) . The resulting PBAE polymers were positively charged and used as the cationic layers for LBL assembly. PBAEs have been used for LBL assembly for the controlled release of DNA [18] , in which DNA is negatively charged and PBAE serves as the cationic layers during LBL assembly. Proteins can be either positively or negatively charged depending on the pKa of the proteins of interest, therefore protein has been used both as the anionic or cationic layer during LBL assembly [19] .   1  2  3  4  CS  CS  CS  CS  7ND  7ND  7ND  7ND  CS  CS  CS  CS  C32-130 C32-135 C32-145 C32-117  CS  CS  CS  CS  C32-130 C32-135 C32-145 C32-117   5  6  7  8  PSS  PSS  PSS  PSS  7ND  7ND  7ND  7ND  PSS  PSS  PSS  PSS  C32-130 C32-135 C32-145 C32-117  PSS  PSS  PSS  PSS  C32-130 C32-135 C32-145 C32-117   9  10  11  12  PSS  PSS  PSS  PSS  7ND  7ND  7ND  7ND Fig. 3 . A combinatorial study to examine the effects of varying polyelectrolyte structure and deposition order on preventing burst release of 7ND from the LBL coating. (A) Schematic design of a total of 16 groups was screened with varying polycation structures and order of polyelectrolyte deposition. The precursor layers were shown on the bottom, and biological layers containing 7ND on the top. All LBL deposition were performed at pH7, with the exception of groups 9e12, in which polycations were dissolved in sodium acetate and performed at pH5. 7ND was dissolved in H 2 O for all groups, with the exception of groups 13e16 where 7ND was suspended in 0.1% (w/v) BSA solution. (B) Percentage of 7ND released within the first 24 h showed burst release in most groups. Groups 1 and 2 (using C32-130 or C32-135 throughout layers at pH7) were identified as optimal combinations with no burst release. CS: chondroitin sulfate, PSS: Polystyrene sulfonate.
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MCP-1 has a pKa of 9.81, therefore it is expected to be positivelycharged at neutral pH, and 7ND is expected to have a similar pKa given its structural similarity to MCP-1.
The choice of polyelectrolytes modulates the initial burst release of 7ND from LBL coating
LBL deposition and release can be influenced by a number of factors including polyelectrolyte structure, layering order and pH. One of greatest challenges in applying LBL coating for drug release is the initial burst release of biomolecules, and prior LBL design often required the use of a few hundred layers to prevent the initial burst release [13, 20, 21] To identify an LBL coating design using a few layers while minimizing the initial burst release from LBL coating, we performed a combinatorial screening study and constructed 16 groups of LBL coatings by varying polyelectrolytes of choice for binding 7ND protein, the order of deposition, and pH (Fig. 3A) . We found that polystyrene sulfonate (PSS) resulted in much higher loading efficiency of 7ND than chondroitin sulfate, as total amount of 7ND released from PSS-based LBL coatings were two orders of magnitude higher than the total 7ND released from CS-based LBL coatings (Fig. S1 ). When 7ND was bound to the anionic layers using CS or PSS, all groups (Groups 1e8) resulted a rapid initial burst release within 1 h (Fig. 3B and Fig. S1 ). This may in part explain the high number of layers required when using the anionic layer as the protein binding layers in previous studies [13, 20, 21] . When 7ND was bound to cationic layers using PBAE polymers (Groups 9e16), loading efficiency was further increased as shown by the total amount of released 7ND protein (Fig. S1) . LBL coatings constructed at pH5 generally resulted in a burst release (Groups 9e12), whereas LBL coating constructed at neutral pH using BSA-containing 7ND proteins overcame the rapid burst and extended release beyond 48 h. The presence of BSA resulted in an overall negative charge in the 7ND protein solution, which we speculate to enhance the binding between the 7ND protein layer and the underlying positively charged PBAE layer. The presence of BSA will also preserve the concentration and structure of 7ND during the loading process by preventing adhesion to the surrounding well. Using C32-130 and C32-135 as the cationic polyelectrolytes resulted in a gradual release from LBL coatings within the first 70 h. C32-130 also led to higher amount of total 7ND release and was chosen for further experiments. 
Microscopy imaging confirmed effective 7ND loading using LBL coating
Successful 7ND loading via LBL deposition was confirmed by SEM and fluorescent microscopy. Un-coated rods have an un-even surface with pits resulting from etching in hydrochloric acid, which was applied to decontaminate the implant surface and increase surface area for polyelectrolyte binding (Fig. 4A and C) . Following the LBL coating, the etched pits were largely filled with the protein coating, creating a smooth appearance on the surface of the implants (Fig. 4B and D) . As the protein coating mainly resides within the pits, it may also help minimize delamination of the coating during the press-fit implantation procedure. The presence of 7ND within the coating was also confirmed through immunolabeling, which showed uniform coating of 7ND across the titanium rod (Fig. 4F) , and minimal background signal can be observed prior to the coating (Fig. 4E) .
Gradual 7ND release can be controlled by varying PBAE chemistry
To further modulate prolonged release of 7ND over time, we synthesized two PBAE polymers terminated with the optimal end group (130) with different degradation rate (C and D). Polymer C contains 4 consecutive carbons in the backbone while polymer D contains 6 consecutive carbons, hence polymer D has increased hydrophobicity and is expected to degrade more slowly. We expect slower degradation would lead to more stable LBL assembly, thereby prolonged protein release over time. This was confirmed by the accumulated 7ND protein release data (Fig. 5) , in which C32-130 released protein over a 2 day period while D32-130 continued to release protein up to day 7. D32-130 also led to 6-fold higher amount of total released 7ND protein compared to C32-130 (Fig. 5) . Previous LBL studies have demonstrated controlled protein release over a similar time frame, however over 100 layers were required to achieve the delayed release [20] . In the current study, we achieved controlled release of proteins using only 14 layers in total, with 4 layers containing 7ND. The rate of protein diffusion may be delayed by increasing the number of layers applied to the implant surface which will also result in a higher amount of 7ND loading. Likewise, the concentration of 7ND released from the implant surface may be increased by using a higher concentration of 7ND during the layering process [15] . In the current study, we have used a concentration of 30 mg/ml 7ND, while previous studies have used growth factor concentrations up to 75 mg/ml for [15] . Interestingly, D32-130 released significantly more 7ND than C32-130. The results suggest that D32-130 has a greater affinity for 7ND or perhaps D32-130 enhances growth rate of the LBL assembly. As each layer is influenced by the charge and homogeneity of the underlying layer, it is possible that D32-130 encourages deposition of the proceeding layer, hence increasing the final concentration of 7ND on the coated implant surface.
Degradation of LBL coating on implant surface
Previous LBL studies have suggested that biomolecule release from LBL assembly is influenced by both diffusion and polymer degradation [22] . To monitor the degradation of LBL coating over time, SEM analysis was performed on titanium rods coated using D32-130 for up to 21 days (Fig. 6 ). Uncoated rods showed etched pits with clearly defined edges, which was covered by a smoother coating after the LBL assembly. SEM showed minimal degradation of the coating on the implant surface over the first 7 days, which suggest that diffusion is likely to be the primary mechanism by which 7ND gets released from the coating. The coating remains visible until day 15, and titanium substrate became visible at day 21. Therefore protein release over 1 week is likely to be modulated by both diffusion and layer degradation. As the goal of the present study is to develop an anti-inflammatory coating, the prolonged presence of non-degradable polymers would be less desirable. The PBAE polymers used in our study are hydrolytically degradable, which facilitates the clinical translation of the platform. It should be noted that polymer concentration in the peri-implant space would be minimal as the LBL coatings are generally nanoscale [23, 24] .
Released 7ND retained its bioactivity to inhibit THP-1 cell migration
In our study, LBL deposition was performed in aqueous conditions and neutral pH to facilitate the retention of protein bioactivity. We have previously shown that fibroblast growth factor retains its activity when released from a similar LBL assembly [15] . To confirm that released 7ND protein retained its biological activity, we examined the ability of released 7ND to inhibit THP-1 cell migration towards MCP-1 using a trans-well migration assay. When no MCP-1 is applied and no 7ND is present, minimal cell migration was observed. MCP-1 induced substantial THP-1 cell migration, and supernatant from LBL coatings that do not contain 7ND (PBS/BSA) did not reduce cell migration. In contrast, supernatant from titanium rods coated with 7ND using polymers C32-130 or D32-130 substantially reduced THP-1 cell migration towards MCP-1 to a level that is comparable to fresh 7ND (Fig. 7) . These results confirm that 7ND released from the current LBL platform retained its biological activity to modulate inflammatory cell migration.
The LBL coating remained stable after femoral implantation procedure
Most orthopedic implants are designed as press fit implants, therefore one prerequisite for an effective biological coating is to remain stable and overcome de-lamination through such forceful procedure. Delamination is common with techniques such as plasma spraying as the coating can be easily detached during the abrasive implantation procedure, although recent advances have improved bonding strength between implant and coating [25] . To examine the stability of our LBL coating, we implanted titanium rods coated with fluorescently-labeled 7ND into the medullary canal of a mouse femur. Fluorescent microscopy and SEM were employed to characterize the implant surface before and after implantation (Fig. 8) . Fluorescence imaging showed strong fluorescence on the rod surface both before and after the implantation procedure, with no noticeable difference in fluorescence intensity.
SEM analysis also confirmed the presence of LBL coating on the titanium rods, with comparable morphology observed before and after implantation. Quantitative analysis of the fluorescent intensity on the coating also confirmed the implantation procedure did not result in a statistically different level of 7ND protein on the rod surface, suggesting that stability of the LBL platform reported here can meet the demands of orthopedic implantation procedure and withstand the abrasive forces during the press-fit procedure. It should be noted however that these results are based on the forces required to press fit the implant into a mouse femur. Scale up studies are required to determine if the coating will withstand the forces during TJR in humans.
Conclusion
In summary, here we report the development of an LBL-based, biodegradable platform for introducing biological coatings to orthopedic implants to modulate inflammatory responses to wear particles. Our results showed that protein loading and release can be modulated by varying the polyelectrolytes of choice, the polymer chemistry, order of deposition, and pH. Our lead condition resulted in efficient 7ND loading and prolonged release of 7ND for at least 1 week, and released 7ND retained its biological activity to inhibit macrophage migration towards MCP-1. Finally, the LBL coating demonstrated great stability and remained comparable before and after the femoral implantation procedure. Together, our results suggest the LBL platform reported herein as a promising strategy for introducing biological coatings to various orthopedic implants, and prolonged 7ND delivery from such coatings may be used to modulate anti-inflammatory responses to prolong the lifetime of current orthopedic implants. 
